申请人:ADDA Biotech Inc.
公开号:US20150183847A1
公开(公告)日:2015-07-02
The present invention relates to the field of biopharmaceutics, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in a marked reduction in side effects.
本发明涉及生物制药领域,特别是一种蛋白质、蛋白质结合物、制药组合物及其治疗糖尿病的用途。本发明的融合蛋白质是通过连接两个多肽而获得的,其中一个多肽是白细胞介素-1受体拮抗蛋白或类似物,另一个多肽是GLP-1受体结合多肽或类似物,或胰岛素受体结合多肽或类似物,或GIP受体结合多肽或类似物。本发明的融合蛋白质及其结合物在治疗糖尿病方面具有显著的疗效,并且可以以较低剂量使用,从而显著减少副作用。